ReviewFrontiers in allergy2021
Allergic Rhinitis: What Do We Know About Allergen-Specific Immunotherapy?
Review in Frontiers in allergy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Clinical Efficacy of Probiotics for Allergic Rhinitis: Results of an Exploratory Randomized Controlled Trial.Nutrients · 2024Trial
- Knowledge, attitudes, and practice towards allergen-specific immunotherapy in parents with children having allergic rhinitis: a cross-sectional study in Wuxi.BMC pediatrics · 2026Article
- Advances in Nanotechnology-Based Immunomodulatory Strategies for the Treatment of Allergic Rhinitis.International journal of nanomedicine · 2026Review
- Gut microbiome modulation in allergic rhinitis: from current evidence to emerging therapies.Frontiers in allergy · 2026Review
- P2 Receptors as Therapeutic Targets in Allergic Rhinitis: Insights From the Use of Natural Products and Preclinical Studies.Journal of immunology research · 2026Review
- Genes and cells associated with sublingual allergen immunotherapy revealed by integrated transcriptome analysis in allergic rhinitis patients.Frontiers in allergy · 2026Article
- Prospective Evaluation of Specific IgE Profile and Quality-of-Life During Allergen-Specific Immunotherapy with House Dust Mite: A Pilot Study.Medicina (Kaunas, Lithuania) · 2025Article
- Long-Term, Real-World Effectiveness of Allergen Immunotherapy in Children and Adolescents With Allergic Rhinitis and Asthma.Allergy · 2025Article
- Landscape of Aeroallergen Sensitization in Asia.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Review
- Subcutaneous Allergen-Specific Immunotherapy for Allergic Rhinitis: Divergent IgA Responses in Nasal Mucosa and Blood With Validation of B Cell Class-Switching in Lymph Nodes and Blood.Clinical and translational allergy · 2025Article
- Review
- Risk factors for drug resistance in allergen immunotherapy for allergic rhinitis: a systematic review and meta-analysis.Frontiers in allergy · 2025Article
- Immunomodulatory features of MSC-derived exosomes decorated with DC-specific aptamer for improving sublingual immunotherapy in allergic mouse model.Stem cell research & therapy · 2024Article
- Role of allergen immunotherapy and biologics in allergic diseases.Current opinion in immunology · 2024Review
- Novel Approaches to Allergen Immunotherapy for Respiratory Allergies.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens.Immunotherapy · 2024Review
- The effect of subcutaneous and sublingual birch pollen immunotherapy on birch pollen-related food allergy: a systematic review.Frontiers in allergy · 2024Review
- Review
- Allergic rhinitis: Review of the diagnosis and management: South African Allergic Rhinitis Working Group.South African family practice : official journal of the South African Academy of Family Practice/Primary Care · 2023Review
- Allergen-specific immunotherapy by recombinant Der P1 allergen-derived peptide-based vaccine in an allergic mouse model.Immunity, inflammation and disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic rhinitis (AR) is an IgE-mediated disease that is characterized by Th2 joint inflammation. Allergen-specific immunotherapy (AIT) is indicated for AR when symptoms remain uncontrolled despite medication and allergen avoidance. AIT is considered to have been effective if it alleviated allergic symptoms, decreased medication use, improved the quality of life even after treatment cessation, and prevented the progression of AR to asthma and the onset of new sensitization. AIT can be administered subcutaneously or sublingually, and novel routes are still being developed, such as intra-lymphatically and epicutaneously. AIT aims at inducing allergen tolerance through modification of innate and adaptive immunologic responses. The main mechanism of AIT is control of type 2 inflammatory cells through induction of various functional regulatory cells such as regulatory T cells (Tregs), follicular T cells (Tfr), B cells (Bregs), dendritic cells (DCregs), innate lymphoid cells (IL-10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.